Geode Capital Management LLC Grows Stock Position in Tempus AI, Inc. $TEM

Geode Capital Management LLC boosted its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 8.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,870,510 shares of the company’s stock after buying an additional 141,680 shares during the quarter. Geode Capital Management LLC’s holdings in Tempus AI were worth $110,478,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Wellington Shields Capital Management LLC bought a new position in Tempus AI in the 4th quarter valued at $1,393,000. Wellington Shields & Co. LLC bought a new position in Tempus AI in the 4th quarter valued at $614,000. Sectoral Asset Management Inc. grew its position in Tempus AI by 19.7% in the 4th quarter. Sectoral Asset Management Inc. now owns 4,500 shares of the company’s stock valued at $266,000 after acquiring an additional 740 shares during the last quarter. Legal & General Group Plc grew its position in Tempus AI by 14.3% in the 4th quarter. Legal & General Group Plc now owns 558,262 shares of the company’s stock valued at $32,965,000 after acquiring an additional 70,020 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in Tempus AI in the 4th quarter valued at $129,000. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday. Guggenheim cut their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. HC Wainwright cut their price objective on Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Monday, June 1st. Finally, Wolfe Research assumed coverage on Tempus AI in a research report on Tuesday. They issued a “peer perform” rating on the stock. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $68.64.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $46.43 on Friday. The firm has a market cap of $8.34 billion, a P/E ratio of -26.99 and a beta of 3.62. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32. The stock’s fifty day moving average price is $48.89 and its 200-day moving average price is $57.48.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.24) earnings per share. On average, equities research analysts expect that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Ryan M. Bartolucci sold 4,116 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $181,392.12. Following the transaction, the chief accounting officer owned 74,041 shares in the company, valued at approximately $3,262,986.87. This trade represents a 5.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 13,550 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $597,148.50. Following the sale, the chief executive officer directly owned 603,558 shares in the company, valued at approximately $26,598,801.06. The trade was a 2.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 558,557 shares of company stock valued at $26,611,939. Company insiders own 24.26% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.